Schrödinger to Present at Jefferies Healthcare Conference
Get Alerts SDGR Hot Sheet
Join SI Premium – FREE
NEW YORK--(BUSINESS WIRE)-- Schrödinger (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced that management will participate in a fireside chat at the Jefferies Healthcare Conference. The live presentation will take place on Thursday, June 9, 2022, at 3:30 p.m. ET.
The live discussion can be accessed under "News & Events" in the investors section of Schrödinger’s website, https://ir.schrodinger.com/news-and-events/event-calendar and will be archived for approximately seven days.
About Schrödinger
Schrödinger is transforming the way therapeutics and materials are discovered. Schrödinger has pioneered a physics-based software platform that enables discovery of high-quality, novel molecules for drug development and materials applications more rapidly and at lower cost compared to traditional methods. The software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. Schrödinger’s multidisciplinary drug discovery team also leverages the software platform to advance collaborative programs and its own pipeline of novel therapeutics to address unmet medical needs.
Founded in 1990, Schrödinger has over 700 employees and is engaged with customers and collaborators in more than 70 countries. To learn more, visit www.schrodinger.com, follow us on LinkedIn and Twitter, or visit our blog, Extrapolations.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220602005242/en/
Jaren Irene Madden
Schrödinger, Inc.
[email protected]
617-286-6264
Tracy Lessor
Schrödinger, Inc.
[email protected]
617-519-9827
Source: Schrödinger, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Euna Solutions to Unveil Euna AI Across Government Finance Solutions at GFOA’s 2026 Annual Conference
- ProQR Announces Positive Phase 1 Target Engagement Data for AX-0810, Establishing First Clinical Validation of the Axiomer RNA Editing Platform
- 2026 Hainan Cultural and Tourism Promotion Events Held in Hong Kong
Create E-mail Alert Related Categories
Business Wire, Press ReleasesRelated Entities
Jefferies & Co, TwitterSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share